Daniel J. Luckshire Acquires 5,000 Shares of SIGA Technologies, Inc. (OTCMKTS:SIGA) Stock

SIGA Technologies, Inc. (OTCMKTS:SIGA) CFO Daniel J. Luckshire acquired 5,000 shares of the company’s stock in a transaction dated Monday, December 9th. The shares were bought at an average cost of $4.34 per share, with a total value of $21,700.00.

Shares of SIGA Technologies stock traded down $0.02 on Tuesday, hitting $4.34. The stock had a trading volume of 309,534 shares, compared to its average volume of 178,465. SIGA Technologies, Inc. has a one year low of $4.28 and a one year high of $8.09. The stock’s 50-day simple moving average is $5.18 and its two-hundred day simple moving average is $5.37.

SIGA Technologies (OTCMKTS:SIGA) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.03) EPS for the quarter. The company had revenue of $8.11 million for the quarter.

A number of institutional investors have recently made changes to their positions in SIGA. Millennium Management LLC bought a new position in shares of SIGA Technologies during the third quarter valued at about $78,000. Zebra Capital Management LLC boosted its holdings in shares of SIGA Technologies by 312.6% during the third quarter. Zebra Capital Management LLC now owns 230,630 shares of the biotechnology company’s stock worth $1,181,000 after purchasing an additional 174,739 shares during the period. State Street Corp grew its stake in shares of SIGA Technologies by 1.2% in the third quarter. State Street Corp now owns 1,000,539 shares of the biotechnology company’s stock worth $5,123,000 after purchasing an additional 11,924 shares during the last quarter. BBVA USA Bancshares Inc. bought a new stake in shares of SIGA Technologies in the third quarter worth about $67,840,000. Finally, Investment Management of Virginia LLC bought a new stake in shares of SIGA Technologies in the third quarter worth about $52,000. 6.66% of the stock is currently owned by institutional investors and hedge funds.

About SIGA Technologies

SIGA Technologies, Inc is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield).

Read More: How to trade on quiet period expirations

Receive News & Ratings for SIGA Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies and related companies with MarketBeat.com's FREE daily email newsletter.